Stocks in play: Medicenna Therapeutics Corp.
Presented updated clinical results from the monotherapy dose escalation and ongoing expansion portions of the Phase 1/2 ABILITY-1 (ABeta-only IL-2 ImmunoTherapY) study evaluating MDNA11, a long-acting ‘beta-enhanced not-alpha’ interleukin-2 (IL-2) super-agonist, in patients with advanced solid tumors, at the 2024 Annual Meeting of the American Association for Cancer Research (AACR) held in San Diego, CA, on April 9. Medicenna Therapeutics Corp. shares T.MDNA are trading up $0.21 at $1.71.
Read:
Global Efforts Intensify to Address Surging Young Adult Colorectal and Anal Cancer Rates
Harnessing AI's $4.4 Trillion Potential Reshapes the Tech Industry Landscape
Critical Push for US Domestic Nickel Needed to Halt Total Reliance on Questionable Foreign Imports
How Argentina’s New Power Moves Look to Lure Even More Lithium Interest Towards the Country
How Recent Biotech Breakthroughs Are Changing the Fight Against Breast Cancer